Search
Maropitant
go.drugbank.com/drugs/DB11427ExperimentalVet approvedIt was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.
Janssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalThe Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. … A preclinical study in hamsters infected with SARS-COV-2 infection[A220053] showed a single immunization with the vaccine-elicited neutralizing responses and protected against SARS-CoV-2 induced pneumonia
Categories: Complex MixturesSPC2968
go.drugbank.com/drugs/DB06351InvestigationalIt was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult … SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha).
Lersivirine
go.drugbank.com/drugs/DB11649InvestigationalLersivirine has been used in trials studying the treatment of HIV-1.
Categories: RNA-Directed DNA PolymeraseAbt-925 anhydrous free base
go.drugbank.com/drugs/DB33803InvestigationalCategories: Receptors, Dopamine D3, antagonists & inhibitorsCarboprost tromethamine
go.drugbank.com/drugs/DB00429ApprovedInvestigationalA nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Pimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexScopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578] … [A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.
Motixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigationalMotixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. … [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow